Patent ID: 7994197

Claim:
A method comprising: administering dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof to a human suffering from migraine, cluster migraine, pediatric migraine, status migranosis or chronic daily headache; wherein the dihydroergotamine, or a complex, chelate, salt, hydrate, polymorph, or ion pair thereof is administered at a rate such that a mean peak plasma concentration (C max ) of 8-hydroxy dihydroergotamine is less than 10,000 pg/ml, and a mean time to C max (T max ) of 8-hydroxy dihydroergotamine is less than 45 minutes, thereby achieving low adrenergic receptor binding and low side effects of one or more of nausea, chest tightness or pain, blood pressure excursions, or emesis.